PHAXIAM Therapeutics S.A.
PHXM · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | -0.02 |
| FCF Yield | -48.15% | 0.00% | 0.00% | -11.69% |
| EV / EBITDA | -2.33 | 0.00 | 0.00 | -10.83 |
| Quality | ||||
| ROIC | -28.80% | 0.00% | 0.00% | 7.15% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.11 | -13.94 | 20.40 | 0.94 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.04 | 0.00 | 0.00 | 3.88 |
| Interest Coverage | -132.37 | -18.31 | 0.00 | 5.54 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 1.31 |
| Cash Conversion Cycle | -705.99 | 0.00 | 0.00 | -15.87 |